European Journal of Cancer

Papers
(The TQCC of European Journal of Cancer is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies246
The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients231
The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers227
The cost of cancer in Europe 2018169
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment164
Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment139
Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts135
Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)123
European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention120
Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CAC118
Global, regional and national burden of primary liver cancer by subtype116
Consensus on molecular imaging and theranostics in neuroendocrine neoplasms116
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial116
Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts109
Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective108
Effect of organised cervical cancer screening on cervical cancer mortality in Europe: a systematic review107
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis106
The prognostic value of tumour-infiltrating lymphocytes in pancreatic cancer: a systematic review and meta-analysis100
A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation100
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations98
Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008–201698
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR98
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 202296
Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review95
Evidence-based recommendations on categories for extent of resection in diffuse glioma94
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation93
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status88
Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer87
European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 202286
Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials85
A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-1985
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and84
Ramucirumab and durvalumab for previously treated, advanced non–small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study84
The immune landscape of neuroblastoma: Challenges and opportunities for novel therapeutic strategies in pediatric oncology83
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 201981
Evolution of low HER2 expression between early and advanced-stage breast cancer81
Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy79
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoi79
Selenium stimulates the antitumour immunity: Insights to future research77
Clinical practice guidelines for BRCA1 and BRCA2 genetic testing77
Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel pr76
Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey73
Exosomes and exosomal RNAs in breast cancer: A status update71
SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death71
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial70
Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials70
Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review70
Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)70
Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment69
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy66
Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review66
Dutch Oncology COVID-19 consortium: Outcome of COVID-19 in patients with cancer in a nationwide cohort study63
Applications of single-cell and bulk RNA sequencing in onco-immunology62
High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients61
The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients61
Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds60
High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study59
Systemic treatment of brain metastases in non-small cell lung cancer59
Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy58
Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor–induced secondary adrenal insufficiency58
Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma57
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation57
Electrochemotherapy in the treatment of cutaneous malignancy: Outcomes and subgroup analysis from the cumulative results from the pan-European International Network for Sharing Practice in Electrochem57
Practical clinical guidelines of the EOTTD for treatment and referral of gestational trophoblastic disease56
Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis56
Melanoma recognition by a deep learning convolutional neural network—Performance in different melanoma subtypes and localisations56
Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review55
Sentinel lymph node biopsy and morbidity outcomes in early cervical cancer: Results of a multicentre randomised trial (SENTICOL-2)54
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma54
Repurposing anticancer drugs for the management of COVID-1954
Combining CNN-based histologic whole slide image analysis and patient data to improve skin cancer classification52
Survival of patients with early-stage cervical cancer after abdominal or laparoscopic radical hysterectomy: a nationwide cohort study and literature review51
ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients50
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma50
Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications50
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies50
Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline – Update 202250
How to manage patients with corticosteroids in oncology in the era of immunotherapy?50
Sentinel lymph node mapping and intraoperative assessment in a prospective, international, multicentre, observational trial of patients with cervical cancer: The SENTIX trial49
SARS-CoV-2 vaccines for cancer patients: a call to action49
Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma48
Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors48
Therapeutic vaccines for breast cancer: Has the time finally come?48
Immune scores in colorectal cancer: Where are we?48
Economic impact of avoidable cancer deaths caused by diagnostic delay during the COVID-19 pandemic: A national population-based modelling study in England, UK47
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?46
Generating human prostate cancer organoids from leukapheresis enriched circulating tumour cells46
Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: A meta-analysis of randomised clinical trials with immune checkpoint inhibitors46
A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma45
Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?45
Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis45
The first report on coronavirus disease 2019 (COVID-19) vaccine refusal by patients with solid cancer in Italy: Early data from a single-institute survey45
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study45
Long term outcomes of stereotactic body radiation therapy for hepatocellular carcinoma without macrovascular invasion44
Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non–small cell lung cancer44
Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study44
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial44
Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study44
Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943–203644
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program44
Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)44
Impact of aging on immune-related adverse events generated by anti–programmed death (ligand)PD-(L)1 therapies44
The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region44
Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events43
The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience43
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study43
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNO43
The Pan-Immune-Inflammation Value in microsatellite instability–high metastatic colorectal cancer patients treated with immune checkpoint inhibitors42
Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy42
Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis42
Tumour-infiltrating lymphocyte density is associated with favourable outcome in patients with advanced non–small cell lung cancer treated with immunotherapy42
Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non–small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study42
Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Pae42
European trends in breast cancer mortality, 1980–2017 and predictions to 202542
Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC501041
Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy41
COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy41
Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer41
Transplant rejections associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review40
Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: A systematic review and meta-analysis40
Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice40
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study40
PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery40
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib40
Explainable artificial intelligence in skin cancer recognition: A systematic review40
Probiotic supplement attenuates chemotherapy-related cognitive impairment in patients with breast cancer: a randomised, double-blind, and placebo-controlled trial40
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study40
Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organis39
Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligan39
Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article39
CRYODESMO-O1: A prospective, open phase II study of cryoablation in desmoid tumour patients progressing after medical treatment39
Systematic review and meta-analysis on the impact of lung cancer screening by low-dose computed tomography39
Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis38
Pseudoprogression in patients treated with immune checkpoint inhibitors for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer38
Efficacy and safety of BNT162b2 vaccination in patients with solid cancer receiving anticancer therapy – a single centre prospective study38
A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies38
Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer38
A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer37
Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status37
Hematological immune related adverse events after treatment with immune checkpoint inhibitors37
Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer37
A prospective multicentre REFCOR study of 470 cases of head and neck Adenoid cystic carcinoma: epidemiology and prognostic factors37
Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism37
Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non–small-cell lung cancer37
European PanCareFollowUp Recommendations for surveillance of late effects of childhood, adolescent, and young adult cancer36
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 1, monoclonal antibodies, antibody-drug conjugates and bispecific T-cell engagers36
New cancer cases at the time of SARS-Cov2 pandemic and related public health policies: A persistent and concerning decrease long after the end of the national lockdown36
Integration of deep learning-based image analysis and genomic data in cancer pathology: A systematic review36
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials36
Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors36
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population36
A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 201536
A phase I dose-escalation study of oxaliplatin delivered via a laparoscopic approach using pressurised intraperitoneal aerosol chemotherapy for advanced peritoneal metastases of gastrointestinal tract36
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial35
The 2016–2019 ImmunoTOX assessment board report of collaborative management of immune-related adverse events, an observational clinical study35
Immune checkpoint inhibitors for cancer and venous thromboembolic events35
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study35
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study35
Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program35
Bridging the Age Gap in breast cancer: Impact of chemotherapy on quality of life in older women with early breast cancer35
The impact of ARID1A mutation on molecular characteristics in colorectal cancer34
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry34
Deep learning approach to predict sentinel lymph node status directly from routine histology of primary melanoma tumours34
The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non–small-cell lung cancer differ based on PD-L1 expression34
Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis34
Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time34
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies34
Nanoliposomal vaccine containing long multi-epitope peptide E75-AE36 pulsed PADRE-induced effective immune response in mice TUBO model of breast cancer34
Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments34
Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment34
The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients34
Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer33
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial33
COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study33
Effect of apatinib plus neoadjuvant chemotherapy followed by resection on pathologic response in patients with locally advanced gastric adenocarcinoma: A single-arm, open-label, phase II trial33
Head and neck mucosal melanoma: The United Kingdom national guidelines33
A benchmark for neural network robustness in skin cancer classification33
Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials33
Cancer and coronavirus disease 2019; how do we manage cancer optimally through a public health crisis?33
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of th33
Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer33
Emergency presentations in patients treated with immune checkpoint inhibitors33
Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care33
Reducing pain and distress related to needle procedures in children with cancer: A clinical practice guideline32
Phase I dose-escalation study of NBTXR3 activated by intensity-modulated radiation therapy in elderly patients with locally advanced squamous cell carcinoma of the oral cavity or oropharynx32
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with 32
Korean red ginseng for cancer-related fatigue in colorectal cancer patients with chemotherapy: A randomised phase III trial32
Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer32
Meta-analysis of prospective studies evaluating breast cancer detection and interval cancer rates for digital breast tomosynthesis versus mammography population screening31
A phase II study of monalizumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: The I1 cohort of the EORTC-HNCG-1559 UPSTREAM trial31
2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy31
Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: A review31
Deep learning can predict lymph node status directly from histology in colorectal cancer31
Child development at 6 years after maternal cancer diagnosis and treatment during pregnancy31
Immune checkpoint inhibitor–associated sarcoidosis: A usually benign disease that does not require immunotherapy discontinuation31
D2 dissection improves disease-specific survival in advanced gastric cancer patients: 15-year follow-up results of the Italian Gastric Cancer Study Group D1 versus D2 randomised controlled trial30
Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone, do it!30
Robustness of convolutional neural networks in recognition of pigmented skin lesions30
Cost-effectiveness of lung cancer screening with low-dose computed tomography in heavy smokers: a microsimulation modelling study30
Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study30
Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model30
Updated EORTC QLQ-C30 general population norm data for Germany30
Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results30
Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)30
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer30
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)30
Survival after a nationwide adoption of robotic minimally invasive surgery for early-stage cervical cancer – A population-based study30
Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 201929
Understanding the organ tropism of metastatic breast cancer through the combination of liquid biopsy tools29
Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature29
SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients29
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial29
Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer29
Sex-differences in symptoms and functioning in >5000 cancer survivors: Results from the PROFILES registry29
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour29
Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy29
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer29
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations28
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study28
Carvedilol blocks neural regulation of breast cancer progression in vivo and is associated with reduced breast cancer mortality in patients28
Conversion strategies with chemotherapy plus targeted agents for colorectal cancer liver-only metastases: A systematic review28
Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands28
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis28
Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. A risk stratified analysis of survival outcomes28
Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial28
A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer28
Machine learning reveals a PD-L1–independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context28
ACCELERATE – Five years accelerating cancer drug development for children and adolescents28
Spotlight on the treatment of infantile fibrosarcoma in the era of neurotrophic tropomyosin receptor kinase inhibitors: International consensus and remaining controversies28
A review of the international early recommendations for departments organization and cancer management priorities during the global COVID-19 pandemic: applicability in low- and middle-income countries27
Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trials27
Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial27
The EndoPredict score predicts response to neoadjuvant chemotherapy and neoendocrine therapy in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients from27
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events – a retrospective cohort study27
COVID-19 in lung cancer patients receiving ALK/ROS1 inhibitors27
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis27
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations27
Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study27
Ano-uro-genital mucosal melanoma UK national guidelines27
Osimertinib versus osimertinib plus chemotherapy for non–small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical 27
KRAS inhibition in non–small cell lung cancer: Past failures, new findings and upcoming challenges27
Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice26
Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02, O26
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis26
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials26
Poor clinical outcomes of intratumoral dendritic cell–specific intercellular adhesion molecule 3–grabbing non-integrin–positive macrophages associated with immune evasion in gastric cancer26
Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases26
Rare use of patient-reported outcomes in childhood cancer clinical trials – a systematic review of clinical trial registries26
Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study26
Impact of lung metastases on overall survival in the phase 3 SELECT study of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer26
0.037452936172485